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Introduction: We report a case of the rare entity of diabetic neuropathic cachexia, in order to remind clinicians
that these cases still exist.
Case presentation: A 71-year-old Moslem Arab man with type 2 diabetes along with diabetic neuropathic cachexia
complicated by a hyperfunctioning autonomous thyroid nodule, and undiagnosed acromegaly came under our
care. We report the unique challenges as to what are the priorities to consider in the course of investigation and
treatment. This case emphasizes the fast recovery from this remediable disorder, with antineuropathic medication
and exogenous insulin to serve as an anabolic hormone on top of its hypoglycemic effect. Shared pathophysiologic
aspects of diabetic neuropathic cachexia, cancerous etiologies and acute phase response are discussed.
Conclusions: Diabetic neuropathic cachexia is an integral differential diagnosis, whenever an intense neuropathic
pain dominates patient complaints, accompanied with anorexia, weight loss as well as mood and sleep
disturbances. This is an original case report of interest to internists, endocrinologists, diabetologists and pain clinic
practitioners. Raising the suspicion of diabetic neuropathic cachexia early and concomitant to weight loss
investigation, might curtail suffering and prompt early recovery from a severe illness that has a good prognosis.Introduction
Since first reported by Ellenberg [1], the hallmark of
diabetic neuropathic cachexia (DNC) consists of varying
degrees of symmetrical painful sensory neuropathy, as
well as varying degrees of symmetrical motor peripheral
neuropathy. There are also autonomic neuropathy com-
plaints and findings such as constipation, diarrhea, gastro-
paresis, orthostatism and impotence.
Complaints of anorexia, profound weight loss/emaci-
ation of fat and lean mass [2] and emotional instability
including sleep disturbances are remarkable.
The outcome of DNC, once treated adequately, is the
full-to-considerable recovery of weight, emotional instabil-
ity, sensorimotor and autonomic neurological manifesta-
tions. The treatment of DNC consists of the available
antidiabetic treatments (oral medications - metformin and
sulfonylureas, or exogenous insulin injections) along with
a nourishing diet, with variable use of different antineuro-
pathic medications [1-7].
Altogether, the symptoms and signs of DNC prompt a
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reproduction in any medium, provided the ortoxic or alcoholic neuropathy, porphyria or chronic re-
lapsing Guillain–Barré syndrome [3]. Weight loss causes
should be thoroughly investigated, and adequate therapy
should be supplied in a considerable time. Hence, DNC
still imparts major challenges with regard to diagnosis
and management [4].
The starting event and perpetuating course by which
DNC evolves are still assumptive. We present an add-
itional case of this rare entity (30 recorded cases, in 18
reports), since case reports are the sole source of under-
standing the course and treatment of DNC. Our case is
rare in: (a) its complexity of management priorities
amongst other comorbid states (uncontrolled diabetes,
iatrogenic thyroid toxic nodule, and overlooked pituitary
acromegaly); and (b) the iatrogenic impact of specific
treatments upon existing morbidities.Case presentation
A 71-year-old Moslem Arab man with a 29-year dur-
ation of type 2 diabetes mellitus, with diabetic neur-
opathy and nephropathy, presented to our outpatient
clinic, after a three-month period of severe neuropathic
paresthetic pain in four extremities and his buttocks
(saddle paresthesia). The pain estimate was 10/10 visual
analog scale (VAS). Concomitantly, he had lost 20kg ofral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Naccache et al. Journal of Medical Case Reports 2014, 8:20 Page 2 of 5
http://www.jmedicalcasereports.com/content/8/1/20weight, felt anorectic, nervous and sad, had insomnia,
tremors, a feeling of general coldness, and was suffering
from new constipation and orthostatic complaints. Conse-
quent to orthostatism, his antihypertensive medications
were reduced to minimum; ramipril was stopped and
atenolol was decreased.
At admission, he complained of dry mouth, fatigue,
lethargy and a feeling of suffocation. Recent hemoglobin
A1c (9.1%) was achieved on 30 unit/day premixed insulin
and metformin 850mg trice daily. Other laboratory find-
ings revealed moderate anemia and chronic mild/moder-
ate renal failure (Table 1).
A few weeks prior to his visit, he completed negative
thorough endoscopic gastrointestinal testing, as well as
whole-body computed tomography (CT) scans searching
for neoplastic findings. Except for incidental sporadic
lymphangiectasis and an arteriovenous (AV) malforma-
tion found in the small bowel and a thyroidal nodule, all
test results were within normal limits.
He could not recall any changes in facial features,
neither had he noticed an increase in shoe size; he
attributed his rounded thick fingers to years of manual
carpentry.
On physical examination he was pale and distressed.
His blood pressure was 124/63mmHg; pulse, 107 beats
per minute; body weight, 86.9kg; height, 171cm; and
body mass index (BMI), 29.7kg/m2. His facial features
were coarse with thickened lips and wide nostrils; he
had a palmar fine tremor and a systolic murmur of 2/6.
Diminished tendon reflexes were observed in four extre-
mities. There was glove and sock hypoesthesia, and
distal weakness of the hands with normal strength of the
lower extremities. His current illnesses were arterial
hypertension; hearing loss; right carpal tunnel syndrome;
obstructive sleep apnea; hyperlipidemia; hiatus hernia
with reflux; and benign prostatic hypertrophy.Table 1 Abnormal laboratory results at admission
Parameter Units Result Normal range
TSH miu/ml <0.01 0.35–4.94
FT4 pmol/L 38.09 9–19
FT3 pmol/L 6.3 2.66–5.7
HbA1c % 9.1 4.0–6.0
hGH ng/ml 3.9 0.0–0.8
IGF-1 ng/ml 455 18.6–126.2
25OHD3 ng/ml 17.9 30–100
Hgb gr/dl 12.2 13.5–17.5
MCV FL 91 80–98
Creatinine mg/dl 1.62 0.5–1.4
25OHD3, 25-hydroxyvitamin D3; FT, free thyroxine; HbA1c, glycated
hemoglobin; Hgb hemoglobin; hGH, human growth hormone; IGF-1, insulin-like
growth factor-1; MCV, mean cell volume, TSH, thyroid-stimulating hormone.With negative thorough weight loss investigation,
major neoplastic disease and inflammatory bowel disease
were ruled out. Absent relevant complaints of malab-
sorption rendered these diagnoses unlikely.
A thyroid nodule was confirmed by sonography, which
was 3.3cm in diameter. His thyroid stimulating hormone
(TSH) level of 0.19 was reported one month prior to the
repetitive CTs (with iodinated contrast media). It became
suppressed thereafter, with elevated thyroid hormone
levels (Table 1). The thyroid technetium scan showed
asymmetrical goiter and low isotope uptake. Thyroid
radioiodine uptake (RAIU) was 1% and 10% after 2 and
24 hours, respectively. Thyroidal fine needle aspirate
(FNA) was consistent with normal thyroid follicular
findings.
Normal findings were detected in his complete blood
count, liver and kidney functions tests, B12, rheumatic
diseases profile, human immunodeficiency virus (HIV),
testosterone, luteinizing hormone (LH), follicle-stimulat-
ing hormone (FSH), prolactin, C-reactive protein and
transferrin tests.
We hypothesized that this grave neuropathic suffering
underpinned a catabolic and inflammatory mechanism
to drive significant emaciation, and to finally result in
weight loss, anemia and disrupted acute phase reactants
(ferritin and iron). Ferritin was high in contrast to a low
correspondent iron level. Ferritin levels observed over
time showed a prominent decline before iron stores
were replenished (Table 2).
Neurological consultation included physical examin-
ation, electromyography (EMG) and nerve conduction
studies to the lower extremities. Electrophysiological
studies revealed a pattern that was consistent with
sensorimotor axonal polyneuropathy. Gastric solid empty-
ing scintigraphy revealed minimal isotope passage to the
small intestine 3.5 hours after ingestion of a labeled meal.
Biochemical parameters, including growth hormone
(GH) and insulin-like growth factor-1 (IGF-1) levels,
established acromegaly (Table 1); a head magnetic reson-
ance imaging (MRI) scan revealed a small gadolinium-
enhanced pituitary mass of 3 × 5 × 3mm.
The patient’s depressed mood appeared to be mainly
attributable to his remarkable neuropathic pains. Hence,
we attributed his weight loss to the rare diagnosis of
DNC, which accounts for profound weight loss, anorexia,
orthostatism, disordered mood and sleep disturbances.
We posted control of the neuropathic suffering as the
first priority, and ameliorating hyperthyroxinemia as a
secondary requirement; we decided that establishing the
cause of acromegaly and its respective treatment to be
the lowest of the three priorities.
Weight loss investigation was concluded as negative,
after the comprehensive work-up our patient underwent
in his local community-based hospital, he denied alcohol
Table 2 Iron homeostatic parameters at follow-up
Parameter (Units) Normal range Admission 1m 4m 6m 17m 21m
Ferritin (ng/ml) 21.8–275 359 74 44 53 ND 150
Iron (mcg/dl) 50–170 49 40 45 56 30 60
Transferrin (mg/dl) 200–380 221 233 249 ND 205 242
m, month(s).
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satisfying increase in appetite and gained weight parallel
to the decrease in neuropathic suffering (Figure 1). How-
ever, infrequently he experienced protracted post-meal
vomiting, which did not hamper his weight regain. The
gastric emptying test was found to be prominently
prolonged as a result of gastroparesis; later on, he expe-
rienced an increase in protracted post-meal vomiting
once he had been started on a somatostatin analog for
acromegaly.
Neuropathy was treated by maximal pregabaline
(75mg daily adjusted to serum creatinine) and achieved
a pronounced clinical response in respective neuropathic
pains. Our patient’s pain estimate dropped to 4 to 5/10
VAS, concomitantly.
Glycemia treatment, including premix insulin doses,
was increased up to 70 units in order to keep glycemia
relatively under control. This control was achieved
parallel to the clinical and laboratory improvement. A
hemoglobin A1c of 7.5% three months after admission
enabled reconstitution of oral antidiabetics, once gluco-
toxicity had abated. Metformin was reinstituted and
vildagliptin added; both treatments were modified accord-
ing to the patient’s renal status. Hypoglycemic events
prompted a decrease of insulin dosage, and a switch from
premix to basal insulin (daily dosage 28 units). Subse-
quently, our patient experienced a gradual increase in gly-
cemia, which was ascribed to active acromegaly, and the
iatrogenic effect of somatostatin analogs on glucose



























































































Figure 1 Body weight (measured in kilograms) changes
over time.Hyperthyroxinemia was ascribed to contrast media
iodide load, on a preexisting autonomous nodule. His
RAIU uptake was respectively low. His thyroid FNA and
follow-up function test results were consistent with a
benign thyroid nodule. Moderate renal failure was
projected in long-term iodide load disposal. However,
thyroid function indices dropped spontaneously back to
the normal range after eight weeks. His TSH level rever-
ted to pre-evaluation level 16 weeks later.
Acromegaly was hormonally established (Table 1) as a
pituitary adenoma-related acromegaly (by MRI). Echo-
cardiography demonstrated negligible mild intraventric-
ular septal hypertrophy.
Our patient preferred a somatostatin analog over
transsphenoidal adenomectomy. He was started on
lanreotide Autogel® 60mg/month several months after
his first visit. Lanreotide failed to achieve good metabolic
control: his IGF-1 remained elevated (437ng/ml). Our
patient was asked to reconsider pituitary adenomectomy
subsequent to the failure of lanreotide, as well as due to
the untoward effects of lanreotide (aggravated glycemia
deterioration and aggravated gastroparesis-related post-
meal vomiting).
Discussion
The leading presentation was profound weight loss. Not-
withstanding, we entertained the intense neuropathic
suffering as a leading force in this clinical status. Hence,
severe pain management was an appropriate treatment
over a reasonable time scale. The intense neuropathic
suffering took over from weight loss as the leading pres-
entation; it is unusual to have a complaint eclipsing a
substantial physical finding.
Our case brings to mind the importance of physical
distress and its consequences. Beyond the scenario of
deteriorating diabetes control, physical distress became
an etiological factor, rather than a consequence of
catabolism-induced weight loss.
Hyperthyroxinemia was detected consequent to imaging
tests. Since this rapidly improved, it was considered as a
superimposed and innocent thyroid disorder.
Hyperglycemia was relentlessly treated with multiple
daily insulin injections. The maximal insulin dose (70
units/day) employed during the peak neuropathic pain was
found to be far higher compared to that (28 units/day)
needed to achieve an HbA1c level of 7.2% once the
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the catabolic impact of pain.
DNC drives general emaciation, implicating the loss of
fat and lean tissues [5-7]. Increased ferritin [8] marks an
acute phase response similar to that which is seen in
surgery stress [9]. Although different in nature, neuro-
pathic pain is very similar to that driven by surgery. The
final common pathway observed in surgery includes
physical distress and gluconeogenesis from lypolized free
fatty acids, as well as protein breakdown [9]; altogether,
this comprises the hallmark of emaciation in DNC. Iron
is one of the negative acute phase reactants [8]; low
serum iron underpins the notion of acute phase re-
sponse as an executive arm.
Eventually, the decrease in plasma ferritin over time
reflected decreasing inflammation in DNC. Ferritin
declined to match its corresponding low plasma iron
levels (Table 2), rendering itself an unreliable marker of
the global iron homeostasis.
Body weight increase reflected a prominent decrease
in catabolism, as did a steady decline in glycemia level.
A strict diet to control hyperglycemia in circumstances
of anorexia is imprudent and inapplicable in a catabolic
weight loss state. Catabolism is featured by adipose
tissue breakdown with classical symptoms (anorexia and
nausea) of its resultant ketonemia [10].
Weight loss here heralded the underlying cause as
hyperglycemia, not merely being consequent to glycemic
control deterioration due to other reasons.
Lower catabolism means less endogenous glucose
production; this is a way of ameliorating pain as a cata-
bolic vector, and intensive insulin treatment as an anabolic
vector resulted in weight regain in this case. This course
was also reported in a recent similar case report [7].
The acromegaly diagnosis contributed only a little, if
at all, to the core management plan, and the specific
treatment of acromegaly with a somatostatin analog was
started quite late.
Acromegaly as an indolent disease might contribute
to the presence of peripheral neuropathy (sensori-
motor and autonomic) directly by itself, and indirectly
by inducing a consequent diabetic state, which, in
turn, can initiate or worsen peripheral neuropathy.
The interplay of acromegaly-diabetes-neuropathy is
difficult to delineate in terms of which was the pri-
mary etiology and which was a major contributor to
the consequent neuropathy. Notwithstanding, there
are no reports in the medical literature as to an acute
course of acromegaly that might lead to catabolic states.
On the other hand, our case underlies the need for
awareness in routine clinical circumstances (hyperten-
sion, sleep apnea, carpal tunnel syndrome), to make a
vigilant effort into unifying these conditions in a sole
etiology: acromegaly.Conclusions
This case report illustrates the need to treat neuropathic
suffering early and curb its accompanying catabolic state.
Early treatment helped mitigate the urgency to find a
neoplastic etiology, and could make investigations of new
cases affordable on an outpatient basis. Although it is
mandatory to rule out neoplastic etiology, early appropri-
ate treatment is obligatory before establishing etiology.
Our DNC case sheds special light on the order of
clinical considerations that govern the complexity of
coexisting morbidities: profound weight loss, intense
neuropathic pain, uncontrolled diabetes, iatrogenic toxic
thyroid nodule and undiagnosed acromegaly, their
mutual interaction and priorities of each respective
treatment. It also demonstrates the impact of a treat-
ment (lanreotide) of one entity: acromegaly on the con-
trol of other coexisting disorders: hyperglycemia of
diabetes, and vomiting of gastroparesis.
Our DNC case underpins the good prognosis in treat-
ment of DNC; a prognosis that justifies its early detec-
tion and treatment. Finally, DNC is comparable to acute
phase response in its catabolic features of emaciation.Patient’s perspective
My son did not give up. After making many efforts seek-
ing the diagnosis and advice on treatment, my general
practitioner and my internist doctors stated: ‘no way out,
we give up’.
My son did not accept that: ‘there must be a way out’.
My nephrologist was fair and offered me a referral to
consult a diabetologist, a specialist I had never met in
my hometown before.
The diabetologist recalled such a case while he was
discussing weight loss in a professional meeting with an-
other colleague. The diabetologist did not believe he
would see such a rare case before his retirement.
At the end, it paid off remaining stubborn to seek
medical advice elsewhere.Consent
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